These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27155668)

  • 1. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up.
    Bustreo S; Osella-Abate S; Cassoni P; Donadio M; Airoldi M; Pedani F; Papotti M; Sapino A; Castellano I
    Breast Cancer Res Treat; 2016 Jun; 157(2):363-371. PubMed ID: 27155668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients.
    Haroon S; Hashmi AA; Khurshid A; Kanpurwala MA; Mujtuba S; Malik B; Faridi N
    Asian Pac J Cancer Prev; 2013; 14(7):4353-8. PubMed ID: 23992002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
    Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
    Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
    Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
    Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.
    Yagi T; Inoue N; Yanai A; Murase K; Imamura M; Miyagawa Y; Enomoto Y; Nishimukai A; Takatsuka Y; Hirota S; Akazawa K; Miyoshi Y
    Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of Ki67 and clinicopathological features in breast cancer].
    Wang B; Wang X; Wang J; Xuan L; Wang Z; Wang X; Gao J; Zhang H
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):273-5. PubMed ID: 24989913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
    Jerjees DA; Alabdullah M; Green AR; Alshareeda A; Macmillan RD; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2014 Jun; 145(2):317-30. PubMed ID: 24744091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.
    Klintman M; Strand C; Ahlin C; Beglerbegovic S; Fjällskog ML; Grabau D; Gudlaugsson E; Janssen EA; Lövgren K; Skaland I; Bendahl PO; Malmström P; Baak JP; Fernö M
    PLoS One; 2013; 8(12):e81902. PubMed ID: 24324728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
    J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.
    Aleskandarany MA; Green AR; Benhasouna AA; Barros FF; Neal K; Reis-Filho JS; Ellis IO; Rakha EA
    Breast Cancer Res; 2012 Jan; 14(1):R3. PubMed ID: 22225836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
    Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
    Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.